Another multikinase inhibitor Dasatinib, which also inhibit downstream STAT3, increased response rate of the patients with Ph1+ leukemia (CML and ALL) accompanied by LGL lymphocytosis and autoimmune like syndrome such as pleuritis and colitis (Mustjoki et al., 2009; Jalkanen et al., 2010), suggesting that Dasatinib has immunostimulatory activity partly through STAT3 inhibition. The gene discussed is STAT3; the disease is Pleuritis.